Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803142 | 0.97 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6KDM1A | |
| SCHEMBL1485619 | 0.97 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6KDM1A | |
| SCHEMBL1485620 | 0.97 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6KDM1A | |
| SCHEMBL8474760 | 0.97 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6KDM1A | |
| SCHEMBL49445 | 0.91 | HDAC4 (0.36) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL24060404 | 0.81 | — | — | |
| SCHEMBL9934647 | 0.81 | — | — | |
| SCHEMBL1485578 | 0.79 | HSD17B10 (0.44) | KDM1AALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL5807465 | 0.78 | — | — | |
| SCHEMBL510008 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104011089-B | Process for producing alpha-olefin | 出光兴产株式会社 | 2016-08-24 | — | — | CN | claimed |
| EP-3848399-B1 | TRANSITION METAL COMPOUND AND METHOD FOR PRODUCING OLEFIN POLYMER | IDEMITSU KOSAN CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11795188-B2 | Transition metal compound and method for producing olefin polymer | IDEMITSU KOSAN CO., LTD. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20230235202-A1 | PLASTICIZER FOR RESINS | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-07-27 | — | — | US | disclosed |
| EP-4129973-A1 | LITHIUM SULFAMATE DERIVATIVES | Daikin Industries, Ltd. (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-20220149433-A1 | COMPOUND, ELECTROLYTIC SOLUTION ADDITIVE, ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3933999-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, MODULE AND COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-05 | — | — | EP | disclosed |
| EP-3932928-A1 | COMPOUND, ELECTROLYTIC SOLUTION ADDITIVE, ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-05 | — | — | EP | disclosed |
| EP-1231226-A1 | ROLLED POLYPROPYLENE AND INJECTION-MOLDED POLYPROPYLENE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1231236-A1 | POLYPROPYLENE FILM AND MULTILAYERED LAMINATE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1227112-A1 | PROPYLENE POLYMERS AND RESIN COMPOSITION AND MOLDING CONTAINING THE POLYMERS | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-1095951-A1 | PROPYLENE POLYMER AND COMPOSITION CONTAINING THE SAME, MOLDED OBJECT AND LAMINATE COMPRISING THESE, AND PROCESSES FOR PRODUCING PROPYLENE POLYMER AND COMPOSITION CONTAINING THE SAME | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2001-05-02 | — | — | EP | disclosed |
| US-5892100-A | DEHYDROHALOGENATION BY REACTION OF UNSATURATED ACID HALIDES WITH CARBAMATE IN THE PRESENCE OF HINDERED AMINE | NIPPON PAINT CO., LTD. (JP) | 1999-04-06 | — | — | US | disclosed |
| EP-0827953-A2 | Method for producing N-acyl carbamate | Nippon Paint Co., Ltd. (JP) | 1998-03-11 | — | — | EP | disclosed |
| EP-0206621-B1 | PROCESS FOR DISPROPORTIONATING SILANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4144394-A | FLAME RETARDANTS FOR POLYMERS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4062909-A | FIRE RETARDANTS | MONSANTO COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220149433-A1 | COMPOUND, ELECTROLYTIC SOLUTION ADDITIVE, ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | C1S, RER1, CLIC1 | HDAC4 4048/4885HDAC2 1223/4885HDAC8 3510/4885 |
| US-11795188-B2 | Transition metal compound and method for producing olefin polymer | H1-0, C9, C5 | HDAC4 3309/4885HDAC2 1611/4885HDAC8 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.